MOLN
NASDAQMolecular Partners AG
News · 26 weeks27-50%
2026-02-082026-08-02
Mix1290d
- Other6(50%)
- SEC Filings5(42%)
- Earnings1(8%)
Latest news
25 items- SECSEC Form 6-K filed by Molecular Partners AG6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
- PRMolecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with CholangiocarcinomaRandomized Phase 2 study in front-line setting progressing well, with nine sites actively recruiting and patient treatment ongoingData update expected in 2027, with trial completion in 2028Trial-in-progress poster to be presented at ESMO 2026 in October ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announces the dosing of first patients in an investigator-initiated Phase 2 proof-of-concept (POC)
- PRMolecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin RadiotherapeuticsPhase 1/2a trial of MP0712, 212Pb-based DLL3-targeted Radio-DARPin co-developed with Orano Med: Dosing ongoing in first patients; initial data anticipated within the coming months, comprehensive efficacy data expected in 2027Additional compassionate care work now initiated by the Nuclear Medicine Research Institute in South Africa utilizing 225Ac-loaded DLL3 Radio-DARPin, highlighting the versatility of DARPins as isotope agnostic vectorsFIH imaging for MP0726, Radio-DARPin targeting MSLN, planned to start in H2 2026New target nomination in H2 2026, with two INDs planned in 2027 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursua
- SECSEC Form 6-K filed by Molecular Partners AG6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
- PRMolecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712Five sites recruiting in US study of DLL3-targeting 212Pb-labelled Radio-DARPin MP0712 Dosing ongoing in first patients, consecutively moving to subsequent dosing cyclesInitial data anticipated within the coming months, comprehensive efficacy data expected in 2027 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and VILLEJUIF, France, July 02, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners"), and Orano Med, a clinical-stage radiopharmaceutical company and a pioneer in the developme
- SECSEC Form S-8 filed by Molecular Partners AGS-8 - MOLECULAR PARTNERS AG (0001745114) (Filer)
- SECSEC Form 6-K filed by Molecular Partners AG6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
- PRMolecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced it will hold trial-in-progress poster presentations on the Phase 1/2a study of its lead targeted alpha radiotherapy candidate MP0712 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. ASCO takes place May 29-June 2 in Chicago, and SNMMI May 30-Ju
- PRMolecular Partners to Present at TD Cowen's 7th Annual Oncology Innovation SummitZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced that members of the management team will participate in the following upcoming investor conference. TD Cowen's 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA: Fireside chat on Wednesday, May 27, 2026 beginning at 11:30am ET The event will be webcast and available on the Molecular Partners website, under the investors tab. About Molecular Partners AG Molecular Partners AG
- SECSEC Form 6-K filed by Molecular Partners AG6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
- PRMolecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317Lead Radio-DARPin MP0712 progressing in Phase 1/2a trial with multiple clinical sites opening and initial clinical data expected in 2026New data on Radio-DARPins' amenability to range of therapeutic payloads enable isotope-agnostic strategy for expanding pipeline Strong financial position with cash including short-term time deposits of CHF 79 million (approx. USD 100 million), providing runway until late 2027 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin ther
- PRMolecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferencesZURICH-SCHLIEREN, Switzerland and Concord, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics, today announced its attendance and presentations on its lead Radio-DARPin candidate MP0712 at upcoming scientific conferences. Details of the events: NIH National Cancer Institute 2026 Small Cell Lung Cancer Consortium Meeting May 6–7, Rockville, MD, USA Title: Molecular characteristics of MP0712, a clinical stage ²¹²Pb-based Radio-DARPin candidate for targeted anti-DLL3 radiotherapy of small cell lung cancer (SCLC) Session: New Therapy Targe
- SECSEC Form 6-K filed by Molecular Partners AG6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
- PRMolecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodelingPositive Phase 1 data confirm MP0317's tumor-localized CD40 activation with a favorable safety profile in patients with advanced cancer typesPharmacokinetic profile of MP0317 well suited for combination treatment settings, including checkpoint inhibitorsRandomized Phase 2 investigator-initiated trial of MP0317 in front-line cholangiocarcinoma open with patient dosing ongoing ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or t
- PRMolecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate for the treatment of MSLN/EpCAM expressing solid tumors, with preclinical data indicating favorable therapeutic windowMP0712, Radio-DARPin candidate in on-going US Phase 1/2a trial, leverages high affinity to DLL3, half-life extension and DLL3 internalization for high tumor accumulation ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass, April 19, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced the presentation of new p
- SECSEC Form 6-K filed by Molecular Partners AG6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
- PRMolecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General MeetingZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced that Clare Fisher was elected by shareholders to its Board of Directors at the Annual General Meeting (AGM). The appointment, and all other motions proposed by the Board of Directors at the AGM, were approved by the shareholders of the Company by a wide majority. "Clare Fisher is an outstanding addition to our Board and we warmly welcome her.
- SECSEC Form 6-K filed by Molecular Partners AG6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
- PRMolecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of DirectorsZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today published the invitation to the Annual General Meeting 2026 and announced the nomination of Clare Fisher for election as a new member of the Board of Directors (BoD) at the Annual General Meeting. The Annual General Meeting will be held on Tuesday, April 14, 2026, 9:00 am CET (doors open at 8:30 am CET), at JED Events, Zürcherstrasse 39, 8952 Schlieren, Switzerland. Invitation to the Annual Gene
- PRMolecular Partners Presents New Preclinical Data Highlighting Radio-DARPins' Amenability to Multiple IsotopesHighly comparable biodistribution profiles of Radio-DARPin candidates labeled with imaging isotopes 177Lu or 203Pb allows for rapid expansion of pipeline with multiple therapeutic isotopes ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced it will hold an oral presentation outlining new preclinical data on Radio-DARPins at the 3rd Global Radiopharmaceuticals Development Summit, taking place in Shanghai, China on March 19–20, 2026. The
- PRMolecular Partners to Hold Three Poster Presentations at AACR 2026ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced it will present three posters at the American Association for Cancer Research (AACR) 2026 Annual Meeting, taking place April 17-22 in San Diego, California, USA. Details of the presentations at AACR 2026: Logic-gated Switch-DARPin T cell engager with CD2 co-stimulation for improved safety and efficacy in MSLN and EpCAM co-expressing ovarian cancerSession Category: ImmunologySession Tit
- SECSEC Form 6-K filed by Molecular Partners AG6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
- SECSEC Form 6-K filed by Molecular Partners AG6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
- SECSEC Form 20-F filed by Molecular Partners AG20-F - MOLECULAR PARTNERS AG (0001745114) (Filer)
- PRMolecular Partners Reports Highlights and Financial Results for Full Year 2025Initiated US Phase 1/2a study of DLL3-targeting 212Pb-based Radio-DARPin candidate MP0712 for SCLC and other neuroendocrine cancers, co-developed with strategic partner Orano Med; initial data anticipated in 2026Second Radio-DARPin MP0726 targeting MSLN progressing towards first-in-human imaging; nomination of new Radio-DARPin candidates anticipated mid-2026Development agreement signed with leading radio-isotope specialist Eckert & Ziegler, enabling proprietary Radio-DARPin candidates with range of isotopes, including 225Ac Phase 2 investigator-initiated randomized trial of tumor-localized CD40 agonist MP0317 combined with standard-of-care for cholangiocarcinoma; patient dosing ongoingPhase
MOLN FAQ
7 questionsWhat does Molecular Partners AG do?
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist...Where does MOLN stock trade?
Molecular Partners AG (MOLN) is listed on NASDAQ.What sector and industry is MOLN in?
Molecular Partners AG operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Molecular Partners AG go public?
Molecular Partners AG (MOLN) completed its IPO in 2021.What are analysts saying about MOLN?
Molecular Partners AG has had 5 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1300.00 price target on 2026-01-27. Recent price targets range from $800.00 to $1300.00.What companies are similar to MOLN?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare MOLN side-by-side with any of them on Quantisnow.How can I track MOLN on Quantisnow?
Quantisnow aggregates Molecular Partners AG's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MOLN to receive live email and push alerts on every new disclosure.